Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
September 01, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
August 12, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces $75 Million Private Placement Financing

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
August 08, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update

– Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia – – Received U.S. FDA orphan drug designation for VGL101 for the treatment of patients with ALSP – – Prioritizing VGL101 in...
August 02, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
August 01, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
July 28, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
June 07, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia

- Received approval from the Human Research Ethics Committee in Australia to initiate a Phase 1 trial of VGL101 in healthy volunteers at doses above 20 mg/kg - - Considering administration of a 30...
June 01, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
May 12, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights

- Presented key findings enhancing clinical understanding of ALSP at the 2022 American Academy of Neurology Annual Meeting - - Expanded leadership team and board of directors with the appointments...